Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.
Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.
Sells reagent kits that hospitals and labs use up one test at a time, so revenue follows the number of cancer patients tested rather than equipment purchases. Many kits are approved by China's drug regulator alongside specific targeted drugs, so a new drug approval can create demand for a matching test.
In one line: A Chinese Foundation Medicine/QIAGEN for companion diagnostics.
Moat: narrow (regulatory licence, IP / patents). Companion-diagnostic approvals tied to specific approved cancer drugs create lock-in.
Headquarters: Xiamen, Fujian, China · Founded: 2003 · Employees: 1,175
Size Amoy Diagnostics (300685.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.01B, the 2141st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.58 on 18 Nov 2026.
Performance Over six months the shares fell 14.8%, against -6.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +11.0%); the operating margin is 33.8% (peer median 11.0%).
Valuation It trades at 19.3× forward earnings against a peer median of 18.6× (6th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 29.6 points above its cost of capital (8.7% WACC).
Next results Next results expected around 13 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.20B | CN¥1.19B | CN¥1.11B | CN¥1.04B | CN¥840M |
| Revenue growth | — | +7% | +6% | +24% | — |
| Gross profit | CN¥988M | CN¥931M | CN¥889M | CN¥825M | CN¥651M |
| EBITDA | n/a | CN¥420M | CN¥334M | CN¥328M | CN¥196M |
| Net income | CN¥346M | CN¥361M | CN¥255M | CN¥261M | CN¥264M |
| Free cash flow | CN¥346M | CN¥311M | CN¥316M | CN¥261M | CN¥80.9M |
| Capital expenditure | CN¥60.2M | CN¥70.2M | CN¥40.2M | CN¥44.9M | CN¥78.3M |
| Total debt | CN¥168M | CN¥124M | CN¥91.6M | CN¥108M | CN¥53.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Amoy Diagnostics 300685.SZ | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% |
| Qiagen QGEN | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% |
| Brenntag BNR.DE | $9.19B | +2% | 0% | 5% | 14.0× | 0.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300685.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.9% | -1.9% | 7th lowest of 21 |
| 6-month return | -14.8% | -6.8% | 7th lowest of 20 |
| Distance from 52-week high | -27.1% | -28.9% | 10th highest of 21 |
| Revenue growth (TTM) | +6.7% | +11.0% | 8th lowest of 20 |
| Operating margin | 33.8% | 11.0% | 3rd highest of 21 |
| Forward P/E | 19.3× | 18.6× | 6th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 4.9% | 7.3% | 6th least demanding of 15 |
| Growth delivered (Del g) | +10.4% | +11.9% | 7th lowest of 15 |
| Hurdle (Req g minus delivered) | -5.4 pp | -2.6 pp | 5th least demanding of 15 |
| ROIC minus cost of capital | +29.6 pp | +2.8 pp | 2nd highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |